Breaking News Instant updates and real-time market news.

XOM

Exxon Mobil

$59.80 /

-1.76 (-2.86%)

07:25
12/01/21
12/01
07:25
12/01/21
07:25

Exxon Mobil to maintain capital investments of $20B-$25B through 2027

ExxonMobil said it has finalized corporate plans, which increase spending to $15B on greenhouse gas emission-reduction projects over the next six years while maintaining capital investments in its portfolio. The plans support the corporate strategy of continued structural cost savings, investment in low-cost-of-supply and lower-emission products, and further portfolio high-grading, positioning the company to double earnings and cash flow by 2027 versus 2019. The company also announced it is on track to meet its 2025 greenhouse gas emission-reduction plans by year-end 2021, four years ahead of schedule. In addition, ExxonMobil has developed more aggressive plans for further Scope 1 and Scope 2 reductions through 2030, consistent with Paris Agreement pathways. ExxonMobil plans to maintain capital investments in the range of $20B-$25B per year through 2027 with flexibility to adjust to adverse market conditions or changes in policy and technology for low-emissions projects. Projected growth of cash flow and earnings in the Upstream business results from cost reductions and progressing advantaged investments in low-cost-of-supply projects in Guyana, Brazil, and the Permian Basin in the United States. More than 90% of Upstream planned capital investments through 2027 are expected to generate returns of greater than 10% at prices less than or equal to $35 per barrel of oil equivalent, while reducing Upstream GHG emissions intensity by 40%-50% through 2030, compared to 2016 levels. Downstream and Chemical earnings and cash flow growth plans are focused on high-return projects, which are expected to double the volume of performance chemicals and lower-emission fuels and lubricants. The company will leverage its manufacturing scale, integration, and technology position to high-grade its portfolio and reduce costs, while optimizing operations and leveraging the capabilities of the Low Carbon Solutions business to reduce greenhouse gas emission intensity at operated facilities. Increased cash flow and earnings enable both further debt reduction and returns to shareholders. It has also announced a $10B share-repurchase program over 12-24 months that will commence in 2022, and it increased its annual dividend payment for the 39th consecutive year. As part of its plan, ExxonMobil has committed $15B for lower-emission investments through 2027. These investments will include a balance between projects to reduce greenhouse gas emissions from existing operations and increased investments in the Low Carbon Solutions business.

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
American Society of Clinical Oncology (ASCO) to hold a symposium » 04:55
01/22/22
01/22
04:55
01/22/22
04:55
AGEN

Agenus

$2.70 /

-0.055 (-2.00%)

, AZN

AstraZeneca

$59.10 /

-1.1 (-1.83%)

, BAYRY

Bayer

$14.62 /

-0.26 (-1.75%)

, BMY

Bristol-Myers

$63.56 /

-1.045 (-1.62%)

, CRDF

Cardiff Oncology

$3.70 /

-0.18 (-4.65%)

, DSNKY

Daiichi Sankyo

$22.66 /

-0.03 (-0.13%)

, DCPH

Deciphera

$8.05 /

-0.1 (-1.23%)

, DNA

Ginkgo Bioworks

$5.27 /

+0.165 (+3.23%)

, ESALY

Eisai

$51.92 /

-0.78 (-1.48%)

, EXAS

Exact Sciences

$74.06 /

-2.005 (-2.64%)

, EXEL

Exelixis

$17.34 /

+0.29 (+1.70%)

, GH

Guardant Health

$70.17 /

-2.36 (-3.25%)

, HCM

Hutchmed

$28.82 /

-1.16 (-3.87%)

, IMMVF

Immunovia

$7.40 /

+ (+0.00%)

, INCY

Incyte

$74.77 /

-0.05 (-0.07%)

, IPSEY

Ipsen

$23.66 /

+0.38 (+1.63%)

, LLY

Eli Lilly

$243.12 /

-0.01 (-0.00%)

, MRK

Merck

$79.98 /

-0.765 (-0.95%)

, MRTX

Mirati Therapeutics

$114.10 /

-4.4 (-3.71%)

, NTRA

Natera

$62.74 /

-0.355 (-0.56%)

, NVCR

Novocure

$67.14 /

-2.9 (-4.14%)

, NVS

Novartis

$87.01 /

-1.18 (-1.34%)

, ORIC

Oric Pharmaceuticals

$10.96 /

-0.37 (-3.27%)

, PBLA

Panbela Therapeutics

$1.60 /

-0.09 (-5.33%)

, PFE

Pfizer

$52.78 /

-1.3 (-2.40%)

, SGEN

Seagen

$127.66 /

-4.85 (-3.66%)

, TPTX

Turning Point Therapeutics

$35.95 /

+0.07 (+0.20%)

, VCYT

Veracyte

$27.00 /

-0.69 (-2.49%)

, ZYME

Zymeworks

$11.20 /

-0.38 (-3.28%)

ASCO Gastrointestinal…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AGEN Agenus
$2.70 /

-0.055 (-2.00%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

DSNKY Daiichi Sankyo
$22.66 /

-0.03 (-0.13%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

ESALY Eisai
$51.92 /

-0.78 (-1.48%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

HCM Hutchmed
$28.82 /

-1.16 (-3.87%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

NVCR Novocure
$67.14 /

-2.9 (-4.14%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

12/16/21 H.C. Wainwright
Agenus initiated with a Buy at H.C. Wainwright
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
10/25/21 B. Riley
Agenus price target lowered to $11 from $12 at B. Riley
AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/16/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

11/15/21 AlphaValue/Baader
Bayer upgraded to Buy from Add at AlphaValue/Baader
11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

01/10/22 Piper Sandler
Piper says Century Therapeutics' alliance with Bristol 'transformational'
01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

12/07/21 Baird
Cardiff Oncology initiated with an Outperform at Baird
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
09/09/21 Maxim
Cardiff Oncology price target raised to $25 from $20 at Maxim
09/09/21 Piper Sandler
Cardiff colorectal cancer data 'very consistent,' says Piper Sandler
DSNKY Daiichi Sankyo
$22.66 /

-0.03 (-0.13%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
11/08/21 Canaccord
Deciphera downgraded to Hold at Canaccord
DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ESALY Eisai
$51.92 /

-0.78 (-1.48%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

11/18/21 Piper Sandler
Exelixis transferred with Overweight at Piper Sandler
11/03/21 H.C. Wainwright
Exelixis price target lowered to $52 from $65 at H.C. Wainwright
10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
GH Guardant Health
$70.17 /

-2.36 (-3.25%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
HCM Hutchmed
$28.82 /

-1.16 (-3.87%)

09/22/21
Fly Intel: Top five analyst downgrades
09/22/21 Goldman Sachs
Hutchmed downgraded to Neutral from Buy at Goldman Sachs
08/03/21 Jefferies
Hutchmed initiated with a Buy at Jefferies
07/13/21 Cantor Fitzgerald
Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald
IMMVF Immunovia
$7.40 /

+ (+0.00%)

12/22/21 Kempen
Immunovia downgraded to Neutral from Buy at Kempen
INCY Incyte
$74.77 /

-0.05 (-0.07%)

01/18/22 RBC Capital
Incyte upgraded to Outperform at RBC Capital on improving 2022 setup
01/18/22 RBC Capital
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/03/22 Guggenheim
Incyte price target lowered to $104 from $118 at Guggenheim
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

01/11/22 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
01/06/22 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
01/04/22 JPMorgan
Ipsen downgraded to Neutral from Overweight at JPMorgan
11/24/21 Berenberg
Ipsen initiated with a Hold at Berenberg
LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

01/21/22 DZ Bank
Eli Lilly upgraded to Buy from Hold at DZ Bank
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
MRK Merck
$79.98 /

-0.765 (-0.95%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
NTRA Natera
$62.74 /

-0.355 (-0.56%)

01/12/22 BTIG
Natera price target lowered to $150, named one of top 2022 picks at BTIG
01/05/22 Piper Sandler
Natera assumed with an Overweight at Piper Sandler
01/04/22 Canaccord
Natera weakness a buying opportunity, says Canaccord
11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
NVCR Novocure
$67.14 /

-2.9 (-4.14%)

01/20/22 Truist
Novocure upgraded to Buy on more favorable risk-reward at Truist
01/20/22 Truist
Novocure upgraded to Buy from Hold at Truist
01/11/22 Wells Fargo
Novocure price target lowered to $70 from $105 at Wells Fargo
01/10/22 Piper Sandler
Novocure price target lowered to $125 from $130 at Piper Sandler
NVS Novartis
$87.01 /

-1.18 (-1.34%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

10/08/21 Baird
Oric Pharmaceuticals price target lowered to $26 from $47 at Baird
10/08/21 Citi
Oric Pharmaceuticals price target lowered to $22 from $33 at Citi
10/08/21 H.C. Wainwright
Oric Pharmaceuticals price target lowered to $30 from $53 at H.C. Wainwright
10/07/21 Oppenheimer
Oppenheimer remains bullish on Oric Pharmaceuticals, says selloff 'overdone'
PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PFE Pfizer
$52.78 /

-1.3 (-2.40%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
SGEN Seagen
$127.66 /

-4.85 (-3.66%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

01/21/22 Oppenheimer
Turning Point Therapeutics price target lowered to $105 from $115 at Oppenheimer
01/03/22 Guggenheim
Turning Point Therapeutics price target lowered to $107 from $118 at Guggenheim
12/22/21 Roth Capital
Turning Point FDA feedback appears positive, says Roth Capital
12/06/21 Cowen
Turning Point Therapeutics initiated with an Outperform at Cowen
VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

01/06/22 Stephens
Veracyte initiated with Overweight, named best idea at Stephens
11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
AGEN Agenus
$2.70 /

-0.055 (-2.00%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

NVCR Novocure
$67.14 /

-2.9 (-4.14%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

  • 11
    Nov
  • 22
    Jul
  • 05
    Feb
AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

ESALY Eisai
$51.92 /

-0.78 (-1.48%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

Periodicals
Judge denies McDonald's motion to dismiss Byron Allen's suit, Bloomberg says  18:33
01/21/22
01/21
18:33
01/21/22
18:33
MCD

McDonald's

$254.64 /

+1.52 (+0.60%)

 
ShowHide Related Items >><<
MCD McDonald's
$254.64 /

+1.52 (+0.60%)

MCD McDonald's
$254.64 /

+1.52 (+0.60%)

01/21/22 BTIG
Beyond Meat's expanded McPlant offering approaching 'national launch', says BTIG
01/19/22 Goldman Sachs
McDonald's price target raised to $287 from $284 at Goldman Sachs
01/14/22 Evercore ISI
Evercore ups Texas Roadhouse to Outperform on underappreciated recovery leverage
01/06/22 UBS
Texas Roadhouse upgraded to Buy from Neutral at UBS
MCD McDonald's
$254.64 /

+1.52 (+0.60%)

MCD McDonald's
$254.64 /

+1.52 (+0.60%)

MCD McDonald's
$254.64 /

+1.52 (+0.60%)

MCD McDonald's
$254.64 /

+1.52 (+0.60%)

Hot Stocks
Gilead says FDA grants expediated approval of Veklury sNDA » 18:25
01/21/22
01/21
18:25
01/21/22
18:25
GILD

Gilead

$68.50 /

+0.68 (+1.00%)

Gilead Sciences, Inc.…

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has granted expedited approval of a supplemental new drug application for Veklury for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role of Veklury, which is the antiviral standard of care for the treatment of patients hospitalized with COVID-19. The expanded indication allows for Veklury to be administered in qualified outpatient settings that can administer daily intravenous infusions over three consecutive days. The FDA has also expanded the pediatric Emergency Use Authorization of Veklury to include non-hospitalized pediatric patients younger than 12 years of age who are at high risk of disease progression. These actions by the FDA come amidst a surge in COVID-19 cases and the reduced susceptibility to several anti-SARS-CoV-2 monoclonal antibodies due to the Omicron variant. In contrast, Veklury targets the highly conserved viral RNA polymerase, thereby retaining activity against existing SARS-CoV-2 variants of concern. In vitro laboratory testing shows that Veklury retains activity against the Omicron variant. To date, no major genetic changes have been identified in any of the known variants of concern that would significantly alter the viral RNA polymerase targeted by Veklury.

ShowHide Related Items >><<
GILD Gilead
$68.50 /

+0.68 (+1.00%)

GILD Gilead
$68.50 /

+0.68 (+1.00%)

01/06/22 Morgan Stanley
Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
12/22/21 Piper Sandler
Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
12/22/21 Morgan Stanley
Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
12/15/21 Jefferies
Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
GILD Gilead
$68.50 /

+0.68 (+1.00%)

GILD Gilead
$68.50 /

+0.68 (+1.00%)

GILD Gilead
$68.50 /

+0.68 (+1.00%)

GILD Gilead
$68.50 /

+0.68 (+1.00%)

Recommendations
Zalando price target lowered to EUR 104 from EUR 110 at Barclays » 17:40
01/21/22
01/21
17:40
01/21/22
17:40
ZLNDY

Zalando

$37.55 /

-0.81 (-2.11%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Zalando to EUR 104 from EUR 110 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
ZLNDY Zalando
$37.55 /

-0.81 (-2.11%)

ZLNDY Zalando
$37.55 /

-0.81 (-2.11%)

12/10/21 UBS
Zalando price target lowered to EUR 101 from EUR 110 at UBS
11/05/21 Morgan Stanley
Zalando price target lowered to EUR 92 from EUR 95 at Morgan Stanley
11/04/21 Barclays
Zalando price target lowered to EUR 110 from EUR 113 at Barclays
11/04/21 Credit Suisse
Zalando price target lowered to EUR 98 from EUR 106 at Credit Suisse
ZLNDY Zalando
$37.55 /

-0.81 (-2.11%)

Recommendations
UniCredit price target raised to EUR 15 from EUR 13.80 at Barclays » 17:39
01/21/22
01/21
17:39
01/21/22
17:39
UNCRY

UniCredit

$7.38 /

-0.2 (-2.64%)

Barclays analyst Paola…

Barclays analyst Paola Sabbione raised the firm's price target on UniCredit to EUR 15 from EUR 13.80 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
UNCRY UniCredit
$7.38 /

-0.2 (-2.64%)

UNCRY UniCredit
$7.38 /

-0.2 (-2.64%)

12/13/21 UBS
UniCredit price target raised to EUR 19.50 from EUR 14.70 at UBS
12/13/21 Credit Suisse
UniCredit price target raised to EUR 15.10 from EUR 13.80 at Credit Suisse
12/13/21 Citi
UniCredit price target raised to EUR 15.70 from EUR 14.10 at Citi
12/10/21 Barclays
UniCredit price target raised to EUR 13.80 from EUR 11.60 at Barclays
UNCRY UniCredit
$7.38 /

-0.2 (-2.64%)

UNCRY UniCredit
$7.38 /

-0.2 (-2.64%)

Recommendations
Trainline price target lowered to 245 GBp from 280 GBp at Barclays » 17:38
01/21/22
01/21
17:38
01/21/22
17:38
TNLIF

Trainline

$4.32 /

+ (+0.00%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Trainline to 245 GBp from 280 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
TNLIF Trainline
$4.32 /

+ (+0.00%)

12/09/21 JPMorgan
Trainline price target lowered to 325 GBp from 358 GBp at JPMorgan
11/04/21 Barclays
Trainline price target lowered to 280 GBp from 340 GBp at Barclays
11/04/21 JPMorgan
Trainline price target lowered to 358 GBp from 399 GBp at JPMorgan
11/04/21 Morgan Stanley
Trainline price target lowered to 380 GBp from 400 GBp at Morgan Stanley
Recommendations
South32 price target lowered to 175 GBp from 180 GBp at Barclays » 17:38
01/21/22
01/21
17:38
01/21/22
17:38
SOUHY

South32

$14.69 /

-0.55 (-3.61%)

Barclays analyst Amos…

Barclays analyst Amos Fletcher lowered the firm's price target on South32 to 175 GBp from 180 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
SOUHY South32
$14.69 /

-0.55 (-3.61%)

01/14/22 Barclays
South32 price target lowered to 180 GBp from 200 GBp at Barclays
12/14/21 Investec
South32 initiated with a Buy at Investec
11/26/21 BMO Capital
South32 price target raised to 210 GBp from 200 GBp at BMO Capital
10/08/21 Barclays
South32 price target raised to 200 GBp from 150 GBp at Barclays
Recommendations
Scout24 price target raised to EUR 70 from EUR 65.50 at Barclays » 17:37
01/21/22
01/21
17:37
01/21/22
17:37
SCOTF

Scout24

$69.93 /

+ (+0.00%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross raised the firm's price target on Scout24 to EUR 70 from EUR 65.50 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
SCOTF Scout24
$69.93 /

+ (+0.00%)

01/20/22 Goldman Sachs
Scout24 resumed with a Neutral at Goldman Sachs
01/14/22 JPMorgan
Scout24 price target lowered to EUR 70 from EUR 71 at JPMorgan
12/13/21 Berenberg
Scout24 initiated with a Buy at Berenberg
12/09/21 JPMorgan
Scout24 upgraded to Overweight from Neutral at JPMorgan
Recommendations
Schibsted price target lowered to NOK 485 from NOK 565 at Barclays » 17:35
01/21/22
01/21
17:35
01/21/22
17:35
SBBTF

Schibsted

$37.04 /

+ (+0.00%)

Barclays lowered the…

Barclays lowered the firm's price target on Schibsted to NOK 485 from NOK 565 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
SBBTF Schibsted
$37.04 /

+ (+0.00%)

01/21/22 Nordea
Schibsted upgraded to Strong Buy from Buy at Nordea
01/20/22 JPMorgan
Schibsted price target lowered to NOK 362 from NOK 438 at JPMorgan
12/10/21 Morgan Stanley
Schibsted downgraded to Equal Weight from Overweight at Morgan Stanley
12/09/21 JPMorgan
Schibsted downgraded to Neutral from Overweight at JPMorgan
Recommendations
Sandvik price target raised to SEK 255 from SEK 252 at Barclays » 17:34
01/21/22
01/21
17:34
01/21/22
17:34
SDVKY

Sandvik

$26.41 /

-0.56 (-2.08%)

Barclays analyst Lars…

Barclays analyst Lars Brorson raised the firm's price target on Sandvik to SEK 255 from SEK 252 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
SDVKY Sandvik
$26.41 /

-0.56 (-2.08%)

SDVKY Sandvik
$26.41 /

-0.56 (-2.08%)

01/21/22 Citi
Sandvik price target raised to SEK 319 from SEK 314 at Citi
01/21/22 Morgan Stanley
Sandvik price target raised to SEK 275 from SEK 269 at Morgan Stanley
01/14/22 Barclays
Sandvik price target raised to SEK 252 from SEK 235 at Barclays
01/13/22 Morgan Stanley
Sandvik price target raised to SEK 269 from SEK 265 at Morgan Stanley
Recommendations
Rio Tinto price target lowered to 4,400 GBp from 4,500 GBp at Barclays » 17:34
01/21/22
01/21
17:34
01/21/22
17:34
RIO

Rio Tinto

$74.36 /

-1.795 (-2.36%)

Barclays analyst Amos…

Barclays analyst Amos Fletcher lowered the firm's price target on Rio Tinto to 4,400 GBp from 4,500 GBp and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

01/20/22 Liberum
Rio Tinto downgraded to Sell from Hold at Liberum
01/14/22 Barclays
Rio Tinto price target raised to 4,500 GBp from 4,200 GBp at Barclays
01/13/22 JPMorgan
Rio Tinto price target lowered to 4,840 GBp from 4,900 GBp at JPMorgan
01/07/22 Berenberg
Rio Tinto upgraded to Buy after underperformance at Berenberg
RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

Recommendations
Rightmove price target raised to 630 GBp from 575 GBp at Barclays » 17:33
01/21/22
01/21
17:33
01/21/22
17:33
RTMVY

Rightmove

$18.01 /

-0.19 (-1.04%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross raised the firm's price target on Rightmove to 630 GBp from 575 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
RTMVY Rightmove
$18.01 /

-0.19 (-1.04%)

01/20/22 Goldman Sachs
Rightmove resumed with a Neutral at Goldman Sachs
10/19/21 JPMorgan
Rightmove price target raised to 753 GBp from 724 GBp at JPMorgan
09/21/21 Citi
Rightmove price target raised to 555 GBp from 450 GBp at Citi
09/15/21 Liberum
Rightmove re-initiated with a Buy at Liberum
Recommendations
Richemont price target raised to CHF 165 from CHF 155 at Barclays » 17:33
01/21/22
01/21
17:33
01/21/22
17:33
CFRUY

Richemont

$14.52 /

-0.64 (-4.22%)

Barclays analyst Carole…

Barclays analyst Carole Madjo raised the firm's price target on Richemont to CHF 165 from CHF 155 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
CFRUY Richemont
$14.52 /

-0.64 (-4.22%)

01/20/22 UBS
Richemont price target raised to CHF 184 from CHF 169 at UBS
01/18/22 Morgan Stanley
Richemont price target raised to CHF 165 from CHF 152 at Morgan Stanley
01/04/22 Barclays
Richemont price target raised to CHF 155 from CHF 150 at Barclays
12/21/21 Bryan Garnier
Richemont upgraded to Buy from Neutral at Bryan Garnier
CFRUY Richemont
$14.52 /

-0.64 (-4.22%)

Recommendations
Prosus price target lowered to EUR 115.90 from EUR 121 at Barclays » 17:32
01/21/22
01/21
17:32
01/21/22
17:32
PROSY

Prosus

$17.32 /

-0.08 (-0.46%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Prosus to EUR 115.90 from EUR 121 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
PROSY Prosus
$17.32 /

-0.08 (-0.46%)

PROSY Prosus
$17.32 /

-0.08 (-0.46%)

01/20/22 Goldman Sachs
Prosus resumed with a Buy at Goldman Sachs
01/10/22 Credit Suisse
Prosus price target lowered to EUR 137 from EUR 140 at Credit Suisse
11/26/21 UBS
Prosus price target raised to EUR 97 from EUR 89 at UBS
11/23/21 JPMorgan
Prosus price target lowered to EUR 114 from EUR 135.90 at JPMorgan
Recommendations
Petra Diamonds price target lowered to 65 GBp from 70 GBp at Barclays » 17:31
01/21/22
01/21
17:31
01/21/22
17:31
PDLMF

Petra Diamonds

$1.10 /

-0.14 (-11.29%)

Barclays analyst Ian…

Barclays analyst Ian Rossouw lowered the firm's price target on Petra Diamonds to 65 GBp from 70 GBp and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
PDLMF Petra Diamonds
$1.10 /

-0.14 (-11.29%)

01/14/22 Barclays
Petra Diamonds price target raised to 70 GBp from 1 GBp at Barclays
10/27/21 Panmure Gordon
Petra Diamonds downgraded to Hold from Buy at Panmure Gordon
Recommendations
Persimmon price target lowered to 2,250 GBp from 2,500 GBp at Barclays » 17:31
01/21/22
01/21
17:31
01/21/22
17:31
PSMMY

Persimmon

$69.72 /

-0.22 (-0.31%)

Barclays analyst Gavin…

Barclays analyst Gavin Jago lowered the firm's price target on Persimmon to 2,250 GBp from 2,500 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
PSMMY Persimmon
$69.72 /

-0.22 (-0.31%)

01/21/22 UBS
Persimmon price target lowered to 2,650 GBp from 3,015 GBp at UBS
01/20/22 Morgan Stanley
Persimmon price target lowered to 2,900 GBp from 3,250 GBp at Morgan Stanley
01/14/22 JPMorgan
Persimmon price target raised to 3,580 GBp from 3,530 GBp at JPMorgan
01/14/22 Deutsche Bank
Persimmon downgraded to Hold from Buy at Deutsche Bank
Recommendations
Naspers price target lowered to ZAR 4,050 from ZAR 4,365 at Barclays » 17:30
01/21/22
01/21
17:30
01/21/22
17:30
NPSNY

Naspers

$33.65 /

-0.67 (-1.95%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Naspers to ZAR 4,050 from ZAR 4,365 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
NPSNY Naspers
$33.65 /

-0.67 (-1.95%)

01/20/22 Goldman Sachs
Naspers resumed with a Buy at Goldman Sachs
11/03/21 Barclays
Naspers price target raised to ZAR 4,370 from ZAR 3,300 at Barclays
10/08/21 Barclays
Naspers price target lowered to ZAR 3,300 from ZAR 3,945 at Barclays
10/04/21 Morgan Stanley
Naspers resumed with an Overweight at Morgan Stanley
Recommendations
Moneysupermarket.com price target lowered to 260 GBp from 275 GBp at Barclays » 17:29
01/21/22
01/21
17:29
01/21/22
17:29
MYSRF

Moneysupermarket.com

$2.57 /

+ (+0.00%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Moneysupermarket.com to 260 GBp from 275 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
MYSRF Moneysupermarket.com
$2.57 /

+ (+0.00%)

12/21/21 Citi
Moneysupermarket.com upgraded to Buy from Neutral at Citi
11/01/21 Credit Suisse
Moneysupermarket.com price target raised to 265 GBp at Credit Suisse
10/20/21 UBS
Moneysupermarket.com price target lowered to 320 GBp from 345 GBp at UBS
10/20/21 Berenberg
Moneysupermarket.com upgraded to Buy from Hold at Berenberg
Recommendations
Hochschild Mining price target lowered to 155 GBp from 160 GBp at Barclays » 17:29
01/21/22
01/21
17:29
01/21/22
17:29
HCHDF

Hochschild Mining

$1.62 /

-0.12 (-6.90%)

Barclays analyst Ian…

Barclays analyst Ian Rossouw lowered the firm's price target on Hochschild Mining to 155 GBp from 160 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
HCHDF Hochschild Mining
$1.62 /

-0.12 (-6.90%)

HCHDF Hochschild Mining
$1.62 /

-0.12 (-6.90%)

01/14/22 Barclays
Hochschild Mining price target lowered to 160 GBp from 165 GBp at Barclays
12/13/21 JPMorgan
Hochschild Mining upgraded to Overweight from Neutral at JPMorgan
11/25/21 BofA
Hochschild Mining upgraded to Buy from Underperform at BofA
11/24/21 BofA
Hochschild Mining downgraded to Underperform from Buy at BofA
Recommendations
HelloFresh price target lowered to EUR 110 from EUR 113 at Barclays » 17:28
01/21/22
01/21
17:28
01/21/22
17:28
HLFFF

HelloFresh

$65.00 /

-2.4 (-3.56%)

Barclays analyst Alvira…

Barclays analyst Alvira Rao lowered the firm's price target on HelloFresh to EUR 110 from EUR 113 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
HLFFF HelloFresh
$65.00 /

-2.4 (-3.56%)

01/14/22 JPMorgan
HelloFresh price target lowered to EUR 68 from EUR 78 at JPMorgan
12/09/21 Barclays
HelloFresh price target raised to EUR 113 from EUR 110 at Barclays
12/09/21 JPMorgan
HelloFresh price target lowered to EUR 78 from EUR 85 at JPMorgan
12/03/21 Deutsche Bank
HelloFresh price target raised to EUR 115 from EUR 107 at Deutsche Bank
HLFFF HelloFresh
$65.00 /

-2.4 (-3.56%)

HLFFF HelloFresh
$65.00 /

-2.4 (-3.56%)

Recommendations
Glencore price target raised to 470 GBp from 450 GBp at Barclays » 17:28
01/21/22
01/21
17:28
01/21/22
17:28
GLNCY

Glencore

$10.89 /

-0.2 (-1.80%)

Barclays analyst Ian…

Barclays analyst Ian Rossouw raised the firm's price target on Glencore to 470 GBp from 450 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
GLNCY Glencore
$10.89 /

-0.2 (-1.80%)

GLNCY Glencore
$10.89 /

-0.2 (-1.80%)

01/19/22 Gordon Haskett
Gordon Haskett notes Nutrien previously a target of BHP after Bloomberg report
01/14/22 Barclays
Glencore price target raised to 450 GBp from 410 GBp at Barclays
01/13/22 JPMorgan
Glencore price target lowered to ZAR 9,700 from ZAR 10,100 at JPMorgan
12/13/21 JPMorgan
Glencore price target lowered to 470 GBp from 480 GBp at JPMorgan
GLNCY Glencore
$10.89 /

-0.2 (-1.80%)

GLNCY Glencore
$10.89 /

-0.2 (-1.80%)

Recommendations
Gem Diamonds price target lowered to 70 GBp from 75 GBp at Barclays » 17:27
01/21/22
01/21
17:27
01/21/22
17:27
GMDMF

Gem Diamonds

/

+

Barclays analyst Amos…

Barclays analyst Amos Fletcher lowered the firm's price target on Gem Diamonds to 70 GBp from 75 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
GMDMF Gem Diamonds
/

+

01/14/22 Barclays
Gem Diamonds price target lowered to 75 GBp from 80 GBp at Barclays
10/07/21 Berenberg
Gem Diamonds upgraded to Buy from Hold at Berenberg
07/08/21 Berenberg
Gem Diamonds downgraded to Hold from Buy at Berenberg
04/07/21 Barclays
Gem Diamonds price target raised to 80 GBp from 62 GBp at Barclays
Recommendations
Fresnillo price target lowered to 880 GBp from 900 GBp at Barclays » 17:27
01/21/22
01/21
17:27
01/21/22
17:27
FNLPF

Fresnillo

$11.23 /

-0.37 (-3.19%)

Barclays analyst Amos…

Barclays analyst Amos Fletcher lowered the firm's price target on Fresnillo to 880 GBp from 900 GBp and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
FNLPF Fresnillo
$11.23 /

-0.37 (-3.19%)

FNLPF Fresnillo
$11.23 /

-0.37 (-3.19%)

12/13/21 JPMorgan
Fresnillo price target raised to 950 GBp from 900 GBp at JPMorgan
11/30/21 RBC Capital
Fresnillo price target lowered to 1,025 GBp from 1,075 GBp at RBC Capital
10/28/21 JPMorgan
Fresnillo price target lowered to 900 GBp from 950 GBp at JPMorgan
10/18/21 UBS
Fresnillo upgraded to Neutral from Sell at UBS
Syndicate
Aziyo Biologics files to sell 3.3M shares of Class A common stock for holders  17:24
01/21/22
01/21
17:24
01/21/22
17:24
AZYO

Aziyo Biologics

$6.09 /

-0.24 (-3.79%)

 
ShowHide Related Items >><<
AZYO Aziyo Biologics
$6.09 /

-0.24 (-3.79%)

AZYO Aziyo Biologics
$6.09 /

-0.24 (-3.79%)

11/09/21 Piper Sandler
Aziyo Biologics price target lowered to $11 from $14 at Piper Sandler
10/25/21 Piper Sandler
Medtronic exit from Aziyo Biologics deal not unexpected, says Piper Sandler
06/10/21 Truist
Aziyo Biologics price target lowered to $16 from $20 at Truist
06/07/21 Piper Sandler
Piper cuts Aziyo target but sees Medtronic sticking with company
AZYO Aziyo Biologics
$6.09 /

-0.24 (-3.79%)

Recommendations
Ferrexpo price target lowered to 265 GBp from 280 GBp at Barclays » 17:24
01/21/22
01/21
17:24
01/21/22
17:24
FEEXF

Ferrexpo

$3.47 /

-0.105 (-2.94%)

Barclays analyst Kennedy…

Barclays analyst Kennedy Nyangoni lowered the firm's price target on Ferrexpo to 265 GBp from 280 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
FEEXF Ferrexpo
$3.47 /

-0.105 (-2.94%)

01/14/22 Barclays
Ferrexpo price target raised to 280 GBp from 240 GBp at Barclays
12/13/21 JPMorgan
Ferrexpo price target raised to 340 GBp from 280 GBp at JPMorgan
12/06/21 JPMorgan
Ferrexpo price target lowered to 280 GBp from 370 GBp at JPMorgan
11/17/21 Credit Suisse
Ferrexpo price target lowered to 350 GBp from 370 GBp at Credit Suisse

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.